A former chief scientific officer and member of the board of directors of the publicly traded biopharmaceutical company Humanigen Inc. was charged with engaging in an insider trading scheme involving the stock of the company, the Justice Department said Monday.
Dale Chappell avoided more than $38 million in losses by selling millions of shares of Humanigen stock while in possession of material nonpublic information about Humanigen’s application to the Food and Drug Administration for approval of a drug to treat Covid-19 called Lenzilumab, the DOJ said.
He faces one count of engaging in a securities fraud scheme and four ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.